DOCSLIB.ORG

Uveitis and Multiple Sclerosis: Potential Common Causal Mutations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Uveitis and Multiple Sclerosis: Potential Common Causal Mutations Molecular Neurobiology (2019) 56:8008–8017 https://doi.org/10.1007/s12035-019-1630-2 Uveitis and Multiple Sclerosis: Potential Common Causal Mutations Alejandra de-la-Torre1 & Claudia T. Silva-Aldana2 & Juliana Muñoz-Ortiz1,3 & Laura B. Piñeros-Hernández2 & Oscar Otero3 & Alejandra Domínguez1 & León A. Faciolince1,3 & Mauricio Arcos-Holzinger1 & Claudio Mastronardi4 & Nora Constanza Contreras-Bravo2 & Carlos Martín Restrepo2 & Mauricio Arcos-Burgos5 Received: 11 March 2019 /Accepted: 26 April 2019 /Published online: 3 June 2019 # The Author(s) 2019 Abstract Uveitis, defined as inflammation of the uveal tract of the eye, is a leading cause of blindness and visual impairment throughout the world. The etiology of uveitis is complex, and autoimmunity plays a major role in its pathogenesis. Intermediate uveitis (IU), a subtype of ocular inflammation, has been associated with systemic autoimmune disorders, specifically with multiple sclerosis (MS). This article reports a rare three-generation family with several members affected by IU (four siblings) and comorbid MS (two siblings fulfilling MS diagnostic criteria and a third sibling presenting some neurological symptoms). Based on the clinical findings, we captured and sequenced whole exomes of seven pedigree members (affected and unaffected). Using a recessive model of transmission with full penetrance, we applied genetic linkage analysis to define minimal critical regions (MCRs) in suggestive or nominal regions of linkage. In these MCRs, we defined functional (some pathogenic), novel, and rare mutations that segregated as homozygous in affected and heterozygous in unaffected family members. The genes harboring these mutations, including DGKI, TNFRSF10A, GNGT1, CPAMD8,andBAFF, which are expressed in both eye and brain tissues and/or are related to autoimmune diseases, provide new avenues to evaluate the inherited causes of these devastating autoimmune conditions. Keywords Uveitis . Multiple sclerosis . Genetics . Mutations . Whole exome sequencing . Pedigree Introduction incidence of uveitis varies between 17.4 and 52.4 new cases per 100,000, and the prevalence is between 38 and 714 per Uveitis is inflammation of the eye’s uveal tract, which in- 100,000. This disease causes 2.8–10% of all cases of blind- cludes the iris, ciliary body, and choroid [1]. The annual ness and visual impairment worldwide, and severity depends on factors such as chronicity and whether or not adjacent Alejandra de-la-Torre, Claudia T. Silva-Aldana and Mauricio Arcos- tissues, such as the retina, optic nerve, and vitreous, are affect- Burgos contributed equally to this work. ed [2–5]. * Alejandra de-la-Torre The Uveitis Nomenclature Standardization (SUN) [email protected] Working Group and the International Uveitis Study Group * Mauricio Arcos-Burgos (IUSG) classify uveitis according to the anatomical location [email protected] of the inflammatory process, i.e., anterior uveitis (iritis, iridocyclitis, and anterior cyclitis), intermediate uveitis (pars 1 Grupo de investigación en neurociencias (NEUROS), Escuela de planitis, posterior cyclitis, and hyalitis), posterior uveitis (fo- Medicina y Ciencias de la Salud, Universidad del Rosario, cal, multifocal, or diffuse choroiditis, chorioretinitis, retinitis, Bogotá, Colombia and neuroretinitis), and panuveitis (anterior chamber, vitreous, 2 ‐ Center For Research in Genetics and Genomics CIGGUR, retina, and choroid) [6–9]. GENIUROS Research Group, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia The etiology of uveitis is complex and involves con- 3 fined autoimmune processes [10], systemic autoimmune Escuela Superior de Oftalmología, Instituto Barraquer de América, Bogotá, Colombia diseases (e.g., multiple sclerosis, Behçet’s disease), infec- 4 tious diseases (e.g., Toxoplasma gondii, Mycobacterium INPAC Research Group, Fundación Universitaria Sanitas, Bogotá, Colombia tuberculosis, Herpes virus,andTreponema pallidum), 5 and inherited genetic susceptibility [11–13]. Previous Grupo de Investigación en Psiquiatría (GIPSI), Departamento de Psiquiatría, Instituto de Investigaciones Medicas (IIM), Facultad de studies reported association of the susceptibility to devel- Medicina, Universidad de Antioquia, Medellin, Colombia op uveitis with polymorphisms in the human lymphocyte Mol Neurobiol (2019) 56:8008–8017 8009 antigen (HLA) class II genes, interleukins 10 and 6 (IL10 and IL6, respectively), tumoral necrosis factor (TNF), transforming growth factor beta 1 and 2 (TGFB1 and TGFB2, respectively), transforming growth factor beta re- ceptor 3 (TGFBR3), interferon gamma (INFG), interleukin 2 receptor subunit alpha (IL2RA), and cytotoxic T lym- phocyte protein 4 (CTLA4), among others [11]. In this article, specific focus is brought to intermedi- ate uveitis (IU) which is the most frequent type of uve- itis associated with MS (61–80%) [14–16]. One expla- nation attributes this association to the ontogenetic rela- tionship between nervous and ocular tissues. An exam- ple of this is the MS demyelination process, which af- Fig. 1 Genealogy segregating intermediate uveitis (IU) and multiple scle- fects both the central nervous system and neuro- rosis (MS). Intermediate uveitis (black signals condition of interest). ophthalmic tracts [16] producing histopathological and Comorbid multiple sclerosis (asterisk) clinical findings common to IU and MS. These include T cells, especially T helper lymphocytes (Th), which Methods infiltrate areas surrounding retinal vessels creating pa- thognomonic histopathological changes known as Bsnow Patients banking^ or Bstrings of pearls^ [17]. Interestingly, pa- tients with MS have autoreactive T cells and antibodies We studied three generations of a family composed of eight directed against glial proteins that are also detected in individuals. Four members of the family were affected by IU snow banking formations. Some authors explain this by (EMU003, EMU004, EMU005, and EMU002) of which two the presence of autoreactive T cells directed toward a also fulfilled diagnostic criteria of MS (EMU005 and common glial epitope present in MS and/or IU patients EMU002), and a third had neurological symptoms suggesting [18]. MS comorbidity (EMU004) (Fig. 1). Briefly, the family is Given that IU and MS are rare disorders, it is unusu- composed of unaffected parents, four siblings, two women al to find patients suffering from both conditions and and two men, the husband of one of the women, and a grand- even less common to find several siblings affected by daughter. IU in all siblings began in childhood (6 to 12 years both conditions. In this manuscript, we report a pedigree old) with episodes of ocular inflammation. A more aggressive with four siblings affected by IU of which two present development of the disease, with a higher incidence of com- sufficient symptoms for the diagnosis of MS (as stated plications, including retinal detachment, was observed in by the revised 2017 McDonald criteria for the diagnosis women (Fig. 2). Consequently, more intensive therapies were of MS) and one presents neurological symptoms that do applied to females (higher doses of steroids and immunosup- not fulfill the McDonald criteria. We hypothesize that pressive drugs, such as methotrexate) (Table 1). Three of the rare/novel genetic variants of major effect shape shared siblings developed neurologic symptoms, including paresthe- genetic susceptibility to both IU and MS. To test this sia and muscular weakness (Table 2). Magnetic resonance hypothesis, we applied whole exome capture and se- imaging of the brain and cervical spine showed the presence quencing and used the resulting genomic variation to of periventricular-demyelinating plaques in affected women determine genetic linkage of potential novel and rare (Figs. 3, 4,and5). Similar to the ocular disease, the neurolog- pathogenic causal mutations with the phenotype. ical symptoms were more aggressive in women than in men Fig. 2 Retinal fluorescein angiography and fundus photography detachment (black arrows). c Intraretinal hemorrhage (asterisk) and reti- EMU005. a Papillitis (circle), cystoid macular edema (white arrow), nal detachment (black arrow) perivasculitis (black arrows), and retinitis (asterisk). b Exudative retinal 8010 Mol Neurobiol (2019) 56:8008–8017 (multiple hospitalizations and treatment with interferon were necessary for women). Females EMU005 and EMU002 ful- filled the revised 2017 McDonald criteria for the diagnosis of MS (Table 2). ids, prednisolone, ids, prednisolone, t, methotrexate Whole Exome Capture, Sequencing, and Bioinformatic Analysis Three methods were used to quantify and qualify DNA: (1) and systemic immunosuppressant, steroids. Systemic corticosteroids, prednisolone, and systemic immunosuppressan methotrexate (higher doses). Systemic corticostero Systemic corticostero and systemic immunosuppressant, methotrexate (higher doses). DNA purity was checked using a NanoDrop spectrophotom- Observation Topic and injected periocular Topic and injected periocular steroids. Topic and injected periocular steroids. eter (Thermo Scientific, Waltham, MA, USA) (OD 260/280 ratio); (2) DNA degradation and contamination were moni- tored on 1% agarose gels; (3) DNA concentration was mea- OS 20/20 OS 20/50 OS 20/20 OS 20/30 sured using a Qubit fluorometer (Thermo Scientific, Waltham, MA, USA). DNAsampleswithOD260/280ratiosbetween1.8and2.0 and concentration above 1.0 μgwereusedtopreparese- quencing libraries. Library preparation for sequencing: Liquid-phase
Load more

Recommended publications
  • Genetic Variation Across the Human Olfactory Receptor Repertoire Alters Odor Perception
    bioRxiv preprint doi: https://doi.org/10.1101/212431; this version posted November 1, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Genetic variation across the human olfactory receptor repertoire alters odor perception Casey Trimmer1,*, Andreas Keller2, Nicolle R. Murphy1, Lindsey L. Snyder1, Jason R. Willer3, Maira Nagai4,5, Nicholas Katsanis3, Leslie B. Vosshall2,6,7, Hiroaki Matsunami4,8, and Joel D. Mainland1,9 1Monell Chemical Senses Center, Philadelphia, Pennsylvania, USA 2Laboratory of Neurogenetics and Behavior, The Rockefeller University, New York, New York, USA 3Center for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, USA 4Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA 5Department of Biochemistry, University of Sao Paulo, Sao Paulo, Brazil 6Howard Hughes Medical Institute, New York, New York, USA 7Kavli Neural Systems Institute, New York, New York, USA 8Department of Neurobiology and Duke Institute for Brain Sciences, Duke University Medical Center, Durham, North Carolina, USA 9Department of Neuroscience, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA *[email protected] ABSTRACT The human olfactory receptor repertoire is characterized by an abundance of genetic variation that affects receptor response, but the perceptual effects of this variation are unclear. To address this issue, we sequenced the OR repertoire in 332 individuals and examined the relationship between genetic variation and 276 olfactory phenotypes, including the perceived intensity and pleasantness of 68 odorants at two concentrations, detection thresholds of three odorants, and general olfactory acuity.
    [Show full text]
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • OR11H6 (NM 001004480) Human Tagged ORF Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC214860L3 OR11H6 (NM_001004480) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: OR11H6 (NM_001004480) Human Tagged ORF Clone Tag: Myc-DDK Symbol: OR11H6 Vector: pLenti-C-Myc-DDK-P2A-Puro (PS100092) E. coli Selection: Chloramphenicol (34 ug/mL) Cell Selection: Puromycin ORF Nucleotide The ORF insert of this clone is exactly the same as(RC214860). Sequence: Restriction Sites: SgfI-MluI Cloning Scheme: ACCN: NM_001004480 ORF Size: 990 bp This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 OR11H6 (NM_001004480) Human Tagged ORF Clone – RC214860L3 OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_001004480.1, NP_001004480.1 RefSeq Size: 993 bp RefSeq ORF: 993 bp Locus ID: 122748 UniProt ID: Q8NGC7, A0A126GVP4 Protein Families: Transmembrane Protein Pathways: Olfactory transduction MW: 36.6 kDa Gene Summary: Olfactory receptors interact with odorant molecules in the nose, to initiate a neuronal response that triggers the perception of a smell.
    [Show full text]
  • Human Artificial Chromosome (Hac) Vector
    Europäisches Patentamt *EP001559782A1* (19) European Patent Office Office européen des brevets (11) EP 1 559 782 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC (43) Date of publication: (51) Int Cl.7: C12N 15/09, C12N 1/15, 03.08.2005 Bulletin 2005/31 C12N 1/19, C12N 1/21, C12N 5/10, C12P 21/02 (21) Application number: 03751334.8 (86) International application number: (22) Date of filing: 03.10.2003 PCT/JP2003/012734 (87) International publication number: WO 2004/031385 (15.04.2004 Gazette 2004/16) (84) Designated Contracting States: • KATOH, Motonobu, Tottori University AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Yonago-shi, Tottori 683-8503 (JP) HU IE IT LI LU MC NL PT RO SE SI SK TR • TOMIZUKA, Kazuma, Designated Extension States: Kirin Beer Kabushiki Kaisha AL LT LV MK Takashi-shi, Gunma 370-1295 (JP) • KUROIWA, Yoshimi, (30) Priority: 04.10.2002 JP 2002292853 Kirin Beer Kabushiki Kaisha Takasaki-shi, Gunma 370-1295 (JP) (71) Applicant: KIRIN BEER KABUSHIKI KAISHA • KAKEDA, Minoru, Kirin Beer Kabushiki Kaisha Tokyo 104-8288 (JP) Takasaki-shi, Gunma 370-1295 (JP) (72) Inventors: (74) Representative: HOFFMANN - EITLE • OSHIMURA, Mitsuo, Tottori University Patent- und Rechtsanwälte Yonago-shi, Tottori 683-8503 (JP) Arabellastrasse 4 81925 München (DE) (54) HUMAN ARTIFICIAL CHROMOSOME (HAC) VECTOR (57) The present invention relates to a human arti- ing a cell which expresses foreign DNA. Furthermore, ficial chromosome (HAC) vector and a method for pro- the present invention relates to a method for producing ducing the same.
    [Show full text]
  • Copy Number Variation in Fetal Alcohol Spectrum Disorder
    Biochemistry and Cell Biology Copy number variation in fetal alcohol spectrum disorder Journal: Biochemistry and Cell Biology Manuscript ID bcb-2017-0241.R1 Manuscript Type: Article Date Submitted by the Author: 09-Nov-2017 Complete List of Authors: Zarrei, Mehdi; The Centre for Applied Genomics Hicks, Geoffrey G.; University of Manitoba College of Medicine, Regenerative Medicine Reynolds, James N.; Queen's University School of Medicine, Biomedical and Molecular SciencesDraft Thiruvahindrapuram, Bhooma; The Centre for Applied Genomics Engchuan, Worrawat; Hospital for Sick Children SickKids Learning Institute Pind, Molly; University of Manitoba College of Medicine, Regenerative Medicine Lamoureux, Sylvia; The Centre for Applied Genomics Wei, John; The Centre for Applied Genomics Wang, Zhouzhi; The Centre for Applied Genomics Marshall, Christian R.; The Centre for Applied Genomics Wintle, Richard; The Centre for Applied Genomics Chudley, Albert; University of Manitoba Scherer, Stephen W.; The Centre for Applied Genomics Is the invited manuscript for consideration in a Special Fetal Alcohol Spectrum Disorder Issue? : Keyword: Fetal alcohol spectrum disorder, FASD, copy number variations, CNV https://mc06.manuscriptcentral.com/bcb-pubs Page 1 of 354 Biochemistry and Cell Biology 1 Copy number variation in fetal alcohol spectrum disorder 2 Mehdi Zarrei,a Geoffrey G. Hicks,b James N. Reynolds,c,d Bhooma Thiruvahindrapuram,a 3 Worrawat Engchuan,a Molly Pind,b Sylvia Lamoureux,a John Wei,a Zhouzhi Wang,a Christian R. 4 Marshall,a Richard F. Wintle,a Albert E. Chudleye,f and Stephen W. Scherer,a,g 5 aThe Centre for Applied Genomics and Program in Genetics and Genome Biology, The Hospital 6 for Sick Children, Toronto, Ontario, Canada 7 bRegenerative Medicine Program, University of Manitoba, Winnipeg, Canada 8 cCentre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada.
    [Show full text]
  • Loss of 18Q22.3 Involving the Carboxypeptidase of Glutamate-Like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer
    Published OnlineFirst November 29, 2011; DOI: 10.1158/1078-0432.CCR-11-1903 Clinical Cancer Imaging, Diagnosis, Prognosis Research Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer Jih-Hsiang Lee1, Elisa Giovannetti4, Jin-Hyeok Hwang1,5, Iacopo Petrini1, Qiuyan Wang1, Johannes Voortman1,4, Yonghong Wang2, Seth M. Steinberg3, Niccola Funel6, Paul S. Meltzer2, Yisong Wang1, and Giuseppe Giaccone1 Abstract Purposes: Pancreatic cancer is the fourth leading cause of cancer-related death, and studies on the clinical relevance of its genomic imbalances are warranted. Experimental Design: Recurrent copy number alterations of cytobands and genes were analyzed by array comparative genomic hybridization (aCGH) in 44 resected pancreatic cancer specimens. Prognostic markers identified by aCGH were validated by PCR gene copy number assay in an independent validation cohort of 61 resected pancreatic cancers. The functions of gene identified were evaluated by proliferation, cell cycle, and migration assays in pancreatic cancer cells. Results: We showed recurrent copy number gains and losses in the first cohort. Loss of 18q22.3 was significantly associated with short-term overall survival in the first cohort (P ¼ 0.019). This cytoband includes the carboxypeptidase of glutamate-like (CPGL) gene. CPGL gene deletion was associated with shorter overall survival in the validation cohort (P ¼ 0.003). CPGL deletion and mutations of TP53 or Kras seem to be independent events. A Cox model analysis of the two cohorts combined showed that loss of 18q22.3/deletion of the CPGL gene was an independent poor prognostic factor for overall survival (HR ¼ 2.72, P ¼ 0.0007).
    [Show full text]
  • Supplementary Methods
    Heterogeneous Contribution of Microdeletions in the Development of Common Generalized and Focal epilepsies. SUPPLEMENTARY METHODS Epilepsy subtype extended description. Genetic Gereralized Epilepsy (GGE): Features unprovoked tonic and/or clonic seizures, originated inconsistently at some focal point within the brain that rapidly generalizes engaging bilateral distributed spikes and waves discharges on the electroencephalogram. This generalization can include cortical and sub cortical structures but not necessarily the entire cortex[1]. GGE is the most common group of epilepsies accounting for 20% of all cases[2]. It is characterized by an age-related onset and a strong familial aggregation and heritability which allows the assumption of a genetic cause. Although genetic associations have been identified, a broad spectrum of causes is acknowledged and remains largely unsolved [3]. Rolandic Epilepsy (RE): Commonly known also as Benign Epilepsy with Centrotemporal Spikes (BECTS), hallmarks early onset diagnosis (mean onset = 7 years old) with brief, focal hemifacial or oropharyngeal sensorimotor seizures alongside speech arrest and secondarily generalized tonic– clonic seizures, which mainly occur during sleep[4]. Rolandic epilepsy features a broad spectrum of less benign related syndromes called atypical Rolandic epilepsy (ARE), including benign partial epilepsy (ABPE), Landau–Kleffner syndrome(LKS) and epileptic encephalopathy with continuous spike-and-waves during sleep (CSWSS)[5]. Together they are the most common childhood epilepsy with a prevalence of 0.2–0.73/1000 (i.e. _1/2500)[6]. Adult Focal Epilepsy (AFE). Focal epilepsy is characterized by sporadic events of seizures originated within a specific brain region and restricted to one hemisphere. Although they can exhibit more than one network of wave discharges on the electroencephalogram, and different degrees of spreading, they feature a consistent site of origin.
    [Show full text]
  • A Rose Extract Protects the Skin Against Stress Mediators: a Potential Role of Olfactory Receptors
    Supplementary data A Rose extract protects the skin against stress mediators: a potential role of olfactory receptors Romain Duroux 1,*, Anne Mandeau 1, Gaelle Guiraudie-Capraz 2, Yannick Quesnel 3 and Estelle Loing 4 1 IFF-Lucas Meyer Cosmetics, Toulouse, France 2 Aix-Marseille University, CNRS, INP, Marseille, France 3 ChemCom S.A., Brussels, Belgium 4 IFF-Lucas Meyer Cosmetics, Quebec, Canada * Correspondence: [email protected] Supplemental methods Keratinocytes cell culture and skin explants Skin organ cultures were prepared from tissues samples derived from volunteers undergoing routine therapeutic procedures, in collaboration with Alphenyx (Marseille). For this study, skin samples were derived from abdominal or breast tissues of healthy women (30-40 years old). Samples were received 1 day post-surgery and used directly for microdissection or cell extraction. Microdissected human skin was cultured at 37°C under 5% CO2, in DMEM (Dutscher, #L0060-500) plus 10% FBS (Sigma Aldrich, #F7524), 1% Penicillin/Streptomycin (Sigma Aldrich, #P0781-100), and 1% of minimum medium non-essential amino acids 10X (Gibco, #11140-035). For keratinocyte culture, cells were isolated from human skin epidermis. Briefly, skin samples were cut into small pieces and immersed in Thermolysin (Sigma Aldrich, #T7902-100mg) at 4°C overnight. Epidermis was then carefully detached from dermis before being incubated with Trypsin-EDTA for 15 minutes at 37°C. Trypsin inhibitor was next added, the mixture centrifuged and the supernatant discarded before adding KGM2 Medium (Promocell, #C- 20011) with 1% Penicillin/Streptomycin (Sigma Aldrich, #P0781-100). NHEK were then maintained in culture at 37 °C under 5 % CO2 and 95 % relative humidity.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • WO 2019/068007 Al Figure 2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/068007 Al 04 April 2019 (04.04.2019) W 1P O PCT (51) International Patent Classification: (72) Inventors; and C12N 15/10 (2006.01) C07K 16/28 (2006.01) (71) Applicants: GROSS, Gideon [EVIL]; IE-1-5 Address C12N 5/10 (2006.0 1) C12Q 1/6809 (20 18.0 1) M.P. Korazim, 1292200 Moshav Almagor (IL). GIBSON, C07K 14/705 (2006.01) A61P 35/00 (2006.01) Will [US/US]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., C07K 14/725 (2006.01) P.O. Box 4044, 7403635 Ness Ziona (TL). DAHARY, Dvir [EilL]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., P.O. (21) International Application Number: Box 4044, 7403635 Ness Ziona (IL). BEIMAN, Merav PCT/US2018/053583 [EilL]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., P.O. (22) International Filing Date: Box 4044, 7403635 Ness Ziona (E.). 28 September 2018 (28.09.2018) (74) Agent: MACDOUGALL, Christina, A. et al; Morgan, (25) Filing Language: English Lewis & Bockius LLP, One Market, Spear Tower, SanFran- cisco, CA 94105 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/564,454 28 September 2017 (28.09.2017) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/649,429 28 March 2018 (28.03.2018) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (71) Applicant: IMMP ACT-BIO LTD.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,703,482 B2 Oshimura Et Al
    USOO8703482B2 (12) United States Patent (10) Patent No.: US 8,703,482 B2 Oshimura et al. (45) Date of Patent: Apr. 22, 2014 (54) HUMAN ARTIFICIAL CHROMOSOME (HAC) Rasheed et al. “Characterization of a Newly Derived Human Sar VECTOR coma Cell Line (HT-1080).” Cancer, 1974, vol. 33, pp. 1027-1033. R. Moreadith etal, “Gene targeting in embryonic stem cells: the new physiology and metabolism.” J Mol Med, 1997, vol. 75, pp. 208-216. (75) Inventors: Mitsuo Oshimura, Tottori (JP); L. Mullins et al., “Perspective Series: Molecular Medicine in Geneti Motonobu Katoh, Tottori (JP); Kazuma cally Engineered Animals: Transgenesis in the Rat and Larger Ani Tomizuka, Gunma (JP); Yoshimi mals,” Journal of Clinical Investigation, 1996, vol. 97, No. 7, pp. Kuroiwa, Gunma (JP); Minoru 1557-1560. Kakeda, Gunma (JP) M. Pera et al. “Human embryonic stem cells,” Journal of Cell Sci ence, 2000, vol. 113, pp. 5-10. Hattori et al. “The DNA sequence of human chromosome 21.” (73) Assignee: Kyowa Hakko Kirin Co., Ltd., Tokyo Nature, 2000, vol. 405, No. 6784, pp. 311-319. (JP) European Search Report dated May 18, 2006 for counterpart appli cation PCT/JP0312734 to parent U.S. Appl. No. 10/530.207. (*) Notice: Subject to any disclaimer, the term of this Y. Kuroiwa et al. “Efficient modification of a human chromosome by patent is extended or adjusted under 35 telomere-directed truncation in high homologous recombination U.S.C. 154(b) by 176 days. proficient chicken DT40 cells.” Nucleic Acids. Res., 1998, vol. 26, No. 14, pp. 3447-3448. Y. Kuroiwa et al., “Manipulation of human minichromosomes to carry (21) Appl.
    [Show full text]